Despite promising preclinical data and a strong rationale for targeting IGF1R, clinical efficacy with anti-IGF1R mabs as single agents or in combination with chemotherapy has been disappointing in EWS, lung cancer and other diseases [18–20, 46, 47]. This evidence concerns the gene IGF1R and lung carcinoma.